Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020

First Treatment Expected In Germany

 
• By Andrew McConaghie

The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment

EMA_Amsterdam
The EMA is now satisfied with bluebird's ‘refined manufacturing specifications’ • Source: EMA

More from Gene Therapies

More from Advanced Therapies